PI
NVCR icon

PEAK6 Investments’s NovoCure NVCR Stock Holding History

PEAK6 Investments’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,107
Closed -$190K – 3916
2024
Q2 		$190K Buy
11,107
+5,107
+85% +$89.8K ﹤0.01% 2778
2024
Q1 		$93.8K Buy
+6,000
New +$88.2K ﹤0.01% 3411
2023
Q2 		– Sell
-347
Closed -$20.9K – 4452
2023
Q1 		$20.9K Buy
+347
New +$27.7K ﹤0.01% 3883
2021
Q3 		– Sell
-1,155
Closed -$256K – 5572
2021
Q2 		$256K Sell
1,155
-10,211
-90% -$1.99M ﹤0.01% 3815
2021
Q1 		$1.5M Buy
+11,366
New +$1.8M ﹤0.01% 2157
2020
Q3 		– Sell
-36,902
Closed -$2.95M – 4721
2020
Q2 		$2.19M Buy
36,902
+15,332
+71% +$1.01M 0.01% 1423
2020
Q1 		$1.45M Buy
21,570
+3,071
+17% +$243K 0.01% 1251
2019
Q4 		$1.56M Buy
+18,499
New +$1.49M 0.01% 1268

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PEAK6 Investments's NVCR Position: Q3 2024 in Review

PEAK6 Investments sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 11,107 shares — an estimated $190K sold.

PEAK6 Investments first reported a position in NVCR in Q4 2019 and held it in 8 quarters. The position peaked at $2.19M in Q2 2020. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • PEAK6 Investments reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • PEAK6 Investments sold 11,107 NovoCure shares in Q3 2024, an estimated $190K.
  • PEAK6 Investments first reported a position in NovoCure in Q4 2019 and held it in 8 quarters.
  • PEAK6 Investments's NovoCure position peaked at $2.19M in Q2 2020.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.